The use of soluble urokinase plasminogen activator receptor (suPAR) as a marker of sepsis in the emergency department setting. A current review

References

• Vincent JL, Marshall JC, Namendys-Silva SA, et al. Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit. Lancet Respir Med. 2014 May;2(5):380–386.
   Google Scholar
• Arefian H, Heublein S, Scherag A, et al. Hospital-related cost of sepsis: A systematic review. J Infect. 2017 Feb;74(2):107–117.
   Google Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017 Mar;43(3):304–377.
   Google Scholar
• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801–810.
   Google Scholar
• de Kruif MD, Limper M, Gerritsen H, et al. Additional value of procalcitonin for diagnosis of infection in patients with fever at the emergency department. Crit Care Med. 2010 Feb;38(2):457–463. PubMed PMID: 20083920.
   Google Scholar
• DeWitt S, Chavez SA, Perkins J, et al. Evaluation of fever in the emergency department. Am J Emerg Med. 2017 Nov;35(11):1755–1758.
   Google Scholar
• Askim Å, Moser F, Gustad LT, et al. Poor performance of quick-SOFA (qSOFA) score in predicting severe sepsis and mortality - a prospective study of patients admitted with infection to the emergency department. Scand J Trauma Resusc Emerg Med. 2017 Jun 9;25(1):56.
   Google Scholar
• Tusgul S, Carron PN, Yersin B, et al. Low sensitivity of qSOFA, SIRS criteria and sepsis definition to identify infected patients at risk of complication in the prehospital setting and at the emergency department triage. Scand J Trauma Resusc Emerg Med. 2017 Nov 3;25(1):108.
   Google Scholar
• Desmedt S, Desmedt V, Delanghe JR, et al. The intriguing role of soluble urokinase receptor in inflammatory diseases. Crit Rev Clin. Lab Sci. 2017;54:117–133.
   Google Scholar
• Gussen H, Hohlstein P, Bartneck M, et al. Neutrophils are a main source of circulating suPAR predicting outcome in critical illness. J Intensive Care. 2019 Apr 27;7:26.
   Google Scholar
• Hayek SS, Sever S, Ko YA, et al. Soluble Urokinase receptor and chronic kidney disease. N Engl J Med. 2015 Nov 12;373(20):1916–1925.
   Google Scholar
• Eugen-Olsen J, Andersen O, Linneberg A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010 Sep;268(3):296–308.
   Google Scholar
• Haupt TH, Petersen J, Ellekilde G, et al. Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study. Crit Care. 2012 Jul 23;16(4):R130.
   Google Scholar
• Sanchis-Gomar F, Bonaguri C, Pareja-Galeano H, et al. Effects of acute exercise and allopurinol administration on soluble urokinase plasminogen activator receptor (suPAR). Clin Lab. 2013;59(1–2):207–210.
   Google Scholar
• Chew-Harris J, Appleby S, Richards AM, et al. Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals. Clin Biochem. 2019 May 23; S0009-9120(19)30022–0. DOI:10.1016/j.clinbiochem.2019.05.010.
   Google Scholar
• Kofoed K, Andersen O, Kronborg G, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care. 2007;11(2):R38.
   Google Scholar
• Uusitalo-Seppälä R, Huttunen R, Tarkka M, et al. Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study. J Intern Med. 2012 Sep;272(3):247–256.
   Google Scholar
• Reichsoellner M, Raggam RB, Wagner J, et al. Clinical evaluation of multiple inflammation biomarkers for diagnosis and prognosis for patients with systemic inflammatory response syndrome. J Clin Microbiol. 2014 Nov;52(11):4063–4066.
   Google Scholar
• Loonen AJ, de Jager CP, Tosserams J. van den Brule AJ, et al. Biomarkers and molecular analysis to improve bloodstream infection diagnostics in an emergency care unit. PLoS One. 2014 Jan 27;9(1):e87315.
   Google Scholar
• Casagranda I, Vendramin C, Callegari T, et al. Usefulness of suPAR in the risk stratification of patients with sepsis admitted to the emergency department. Intern Emerg Med. 2015 Sep;10(6):725–730.
   Google Scholar
• Loonen AJM, Kesarsing C, Kusters R. van den Brule AJC, et al. High pneumococcal DNA load, procalcitonin and suPAR levels correlate to severe disease development in patients with pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis. 2017 Sep;36(9):1541–1547.
   Google Scholar
• Schultz M, Rasmussen LJH, Andersen MH, et al. Use of the prognostic biomarker suPAR in the emergency department improves risk stratification but has no effect on mortality: a cluster-randomized clinical trial (TRIAGE III). Scand J Trauma Resusc Emerg Med. 2018 Aug 28;26(1):69.
   Google Scholar
• Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009;27(3):157–172.
   Google Scholar
• Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002 Dec;3(12):932–943.
   Google Scholar
• Gustafsson A, Ljunggren L, Bodelsson M, et al. The prognostic value of suPAR compared to other inflammatory markers in patients with severe sepsis. Biomark Insights. 2012;7:39–44.
   Google Scholar
• Ni W, Han Y, Zhao J, et al. Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis. Sci Rep. 2016 Dec;19(6):39481.
   Google Scholar
• Koch A, Voigt S, Kruschinski C, et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care. 2011;15:R63.
   Google Scholar
• Donadello K, Scolletta S, Taccone FS, et al. Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients. J Crit Care. 2014 Feb;29(1):144–149.
   Google Scholar
• Savva A, Raftogiannis M, Baziaka F, et al. Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. J Infect. 2011;63:344–350.
   Google Scholar
• Rasmussen LJH, Ladelund S, Haupt TH, et al. Combining national early warning score with soluble urokinase plasminogen activator receptor (suPAR) improves risk prediction in acute medical patients: a registry-based cohort study. Crit Care Med. 2018 Dec;46(12):1961–1968.
   Google Scholar
• Rasmussen LJ, Ladelund S, Haupt TH, et al. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. Emerg Med J. 2016 Nov;33(11):769–775.
   Google Scholar